IGF-1, Growth Hormone, and the Aging Axis: What the Data Shows

Across virtually every species studied — worms, flies, mice — reduced signaling through the GH/IGF-1 axis extends lifespan. Ames dwarf mice with deficient GH live 40–70% longer than normal mice.[2] Growth hormone receptor knockout mice live dramatically longer with reduced cancer and age-related disease.[3] A meta-analysis of 42 survival studies found that reduced GH signaling “robustly” increases lifespan with consistent effects across sexes.[4]

In humans, the Laron syndrome population in Ecuador — born with non-functional GH receptors and very low IGF-1 — are remarkably protected from cancer and diabetes.[5] Centenarian studies consistently find that exceptional longevity associates with reduced IGF-1 and enhanced insulin sensitivity.[6] Meanwhile, acromegaly (GH excess) shortens lifespan dramatically.

The pattern is clear: the pathway that builds you up when you're young appears to break you down when it stays chronically active in later life. Biologists call this antagonistic pleiotropy — and the GH/IGF-1 axis is its poster child.

“Feeling better and living longer are not always the same thing — and the most honest approach targets mid-normal range for age: not so low you're losing muscle and function, not so high you're chronically stimulating proliferative pathways.”

The anti-aging community tends to want upper-normal IGF-1 values (200–250+ ng/mL), arguing for restoring youthful levels. The longevity evidence argues that lower-normal values are protective against cancer and age-related disease. A 2025 review in Endocrine Reviews confirmed a U-shaped relationship: both very high and very low IGF-1 levels associate with increased mortality.[7]

The practical approach: target mid-normal range for age. Low IGF-1 with fatigue and sarcopenia warrants investigation — but not necessarily GH replacement. Often it reflects poor sleep, chronic undereating, untreated hypothyroidism, or chronically elevated cortisol. Fix those and IGF-1 frequently normalizes without pharmacological intervention.

No randomized trial has shown GH replacement extends lifespan in healthy aging adults. The body composition benefits are real — more muscle, less fat, better energy — but so are the risks: insulin resistance, fluid retention, joint pain, and theoretical cancer promotion.[1] Endocrine Society consensus holds that GH replacement is not a viable anti-aging treatment for the general older adult population.[6]

Growth hormone secretagogues (sermorelin, ipamorelin, CJC-1295) are a more nuanced approach that preserves pulsatile GH release, but long-term safety data is limited, and the regulatory landscape around compounded peptides has become significantly more complex.

The most effective interventions for the somatotropic axis are the same ones that form the foundation of any serious health optimization program. Resistance training is the single most potent natural stimulus for GH secretion. Deep slow-wave sleep is when the day's largest GH pulse occurs. Excessive body fat suppresses GH. Chronically elevated insulin suppresses GH. High-protein meals stimulate GH acutely.

Lift heavy things. Sleep deeply. Manage body composition. Don't live on sugar. These interventions support the axis naturally, without the risks — and without the unresolved question of whether pharmacologically restoring “youthful” hormone levels actually serves the biology of a body that may be suppressing them for good reason.

IGF-1 is a genuinely important biomarker. But interpreting it requires the understanding that feeling better and living longer are not always the same thing, and that the most honest approach is to measure, contextualize, optimize lifestyle first, and intervene pharmacologically only with clear clinical justification and informed consent about the paradox at the heart of this axis.